Among malignant tumors affecting women, breast cancer consistently ranks first in incidence. Approximately 70% of cases are hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (HER2)–negative. Endocrine therapy is the cornerstone of treatment for this subtype; however, patients with advanced disease frequently develop resistance, leading to a major...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
